# Clinical Study of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN)

> **NCT07423572** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital of Zhejiang Chinese Medical University** · enrollment: 18 (estimated)

## Conditions studied

- Refractory Idiopathic Membranous Nephropathy

## Interventions

- **DRUG:** CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells (UCAR-T) infusing

## Key facts

- **NCT ID:** NCT07423572
- **Lead sponsor:** The First Affiliated Hospital of Zhejiang Chinese Medical University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-28
- **Primary completion:** 2028-02-28
- **Final completion:** 2029-09-28
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07423572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07423572, "Clinical Study of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07423572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*